Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from protease inhibitor regimen to Biktarvy for cardiovascular risk in people with HIV
2017-005033-22Phase 4Unknown
- Sponsor
- University of Liverpool
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Liverpool. Primary endpoint: Change in coronary plaque on serial CT coronary angiography. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-005033-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005033-22.